Related Experiment Video
Updated: Jul 17, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
Management of patients with HBeAg-negative chronic hepatitis B
Nripen Saikia1, Rupjyoti Talukdar, Subhasish Mazumder
1Department of Gastroenterology, Pushpawati Singhania Research Institute, New Delhi, India. saikia.n@gmail.com
Abstract:
Chronic hepatitis B (CHB) is one of the leading causes of morbidity and mortality worldwide. Although various drugs are available for the treatment of CHB, emergence of the hepatitis B e antigen (HBeAg)-negative mutant variant, specifically in Asia, the Middle East and southern Europe, is creating a new challenge as this variant is less responsive to available treatments. HBeAg-negative CHB rapidly progresses to cirrhosis and its related complications. This review discusses the available literature on the approved and under-trial treatment options and their respective efficacies for HBeAg-negative CHB.
Related Concept Videos
Hepatitis
Viral Hepatitis I: Introduction
Esophageal Varices-II: Clinical Features and Management
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...
Chronic Pancreatitis II: Collaborative Care
Assessment:
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Acute Pancreatitis II: Clinical Manifestations and Management
